Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Perfection is not the point
This table from the National Kidney Foundation shows how they can both be considered: They found that while there was a short drop (eGFR got worse) in the semaglutide group at treatment onset, it came back up and no difference in Cr-eGFR between the semaglutide and placebo groups was observed at week 24. In terms of body weight they found that No correlations were observed between changes in body weight and eGFR during 24-week treatment with semaglutide regardless of whether eGFR was estimated with creatinine or cystatin C or measured with iohexol clearance. They go on to point out that this is a consistent finding in trials of GLP-1 drugs and eGFR
However, these medications may cause side effects and, in some cases, more serious health complications
Typically mild, localized, and resolved by site rotation
Research from the same ENDO 2025 presentation found that greater muscle loss was linked to less improvement in HbA1c levels, the marker for blood sugar control
US$ 20.48
US$ 25.58
US$ 20.32
US$ 29.10
US$ 23.76
US$ 25.62
US$ 27.64
US$ 22.25
